FDA Approves New Obesity Pill Foundayo, Offering Patients More Options
The Food and Drug Administration (FDA) has approved Foundayo, a new obesity pill developed by Eli Lilly. This daily pill is the second GLP-1 pill approved for treating obesity, following the approval of the Wegovy pill by Novo Nordisk. Foundayo offers an alternative to injectable obesity drugs, potentially appealing to patients who prefer oral medication. The approval was fast-tracked by the FDA, highlighting the national priority of addressing obesity. Foundayo is priced at $149 per month for those paying cash, making it a more affordable option compared to some injectable treatments. 
